Urotensin II alters vascular reactivity in animals subjected to volume overload

Peptides

Volumn 31, Issue 11, 2010, Pages 2075-2082

  Harris, Gregory S ^a   Lust, Robert M ^a   Katwa, Laxmansa C ^a   Wingard, Christopher J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Endothelial dependent relaxation; Rat; Rho kinase; Thoracic aorta; Vascular smooth muscle

Indexed keywords

ACETYLCHOLINE; ALPHA 1A ADRENERGIC RECEPTOR; FASUDIL; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; RHO KINASE; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTOCAVAL FISTULA; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; HEART FAILURE; HYPERVOLEMIA; MALE; NONHUMAN; OSMOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; THORACIC AORTA; VASOCONSTRICTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; ARTERIOVENOUS SHUNT, SURGICAL; CARDIAC VOLUME; HEART FAILURE; HUMANS; MALE; MODELS, ANIMAL; NITROPRUSSIDE; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RHO-ASSOCIATED KINASES; UROTENSINS; VASOCONSTRICTION; VENAE CAVAE;

ANIMALIA; FISTULA; RATTUS;

EID: 77957829685     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.07.023     Document Type: Article

References (50)

1. R.S. Ames, H.M. Sarau, J.K. Chambers, R.N. Willette, N.V. Aiyar, and A.M. Romanic Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 Nature 401 6750 (September) 1999 282 286
2. D.J. Behm, S.M. Harrison, Z. Ao, K. Maniscalco, S.J. Pickering, and E.V. Grau Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice Br J Pharmacol 139 2 (May) 2003 464 472
3. K. Budzyn, P.D. Marley, and C.G. Sobey Targeting Rho and Rho-kinase in the treatment of cardiovascular disease Trends Pharmacol Sci 27 2 (February) 2006 97 104
4. G. Christ, and C. Wingard Calcium sensitization as a pharmacological target in vascular smooth-muscle regulation Curr Opin Invest Drugs 6 9 (September) 2005 920 933
5. J.M. Conlon Liberation of urotensin II from the teleost urophysis: an historical overview Peptides 29 5 (May) 2008 651 657
6. M.J. Crespo Vascular alterations during the development and progression of experimental heart failure J Card Fail 5 1 (March) 1999 55 63
7. S.A. Doggrell Urotensin-II and the cardiovascular system - the importance of developing modulators Expert Opin Invest Drugs 13 5 (May) 2004 479 487
8. S.A. Douglas Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol 3 2 (April) 2003 159 167
9. S.A. Douglas, and E.H. Ohlstein Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease Trends Cardiovasc Med 10 6 (August) 2000 229 237
10. S.A. Douglas, L. Tayara, E.H. Ohlstein, N. Halawa, and A. Giaid Congestive heart failure and expression of myocardial urotensin II Lancet 359 9322 (June) 2002 1990 1997
11. S.F. Flaim Peripheral vascular effects of nitroglycerin in a conscious rat model of heart failure Am J Physiol 243 6 (December) 1982 H974 H981
12. R. Garcia, and S. Diebold Simple, rapid, and effective method of producing aortocaval shunts in the rat Cardiovasc Res 24 5 (May) 1990 430 432
13. G. Giebing, M. Tolle, J. Jurgensen, J. Eichhorst, J. Furkert, and M. Beyermann Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction Circ Res 97 7 (September) 2005 707 715
14. G.S. Harris, R.M. Lust, and L.C. Katwa Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula Peptides 28 8 (August) 2007 1483 1489
15. R.H. Hilgers, and R.C. Webb Molecular aspects of arterial smooth muscle contraction: focus on Rho Exp Biol Med (Maywood) 230 11 (December) 2005 829 835
16. C. Hillier, C. Berry, M.C. Petrie, P.J. O'Dwyer, C. Hamilton, and A. Brown Effects of urotensin II in human arteries and veins of varying caliber Circulation 103 10 (March) 2001 1378 1381
17. K. Hirano Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle J Pharmacol Sci 104 2 (June) 2007 109 115
18. A. Ishihata, T. Ogaki, T. Aita, and Y. Katano Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats Eur J Pharmacol 523 1-3 (October) 2005 119 126
19. A. Ishihata, M. Sakai, and Y. Katano Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide Peptides 27 1 (January) 2006 80 86
20. A.M. Katz Proliferative signaling and disease progression in heart failure Circ J 66 3 (March) 2002 225 231
21. T. Kishi, Y. Hirooka, A. Masumoto, K. Ito, Y. Kimura, and K. Inokuchi Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure Circulation 111 21 (May) 2005 2741 2747
22. N. Kobayashi, S. Horinaka, S. Mita, S. Nakano, T. Honda, and K. Yoshida Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts Cardiovasc Res 55 4 (September) 2002 757 767
23. A.R. Kompa, W.G. Thomas, F. See, A. Tzanidis, R.D. Hannan, and H. Krum Cardiovascular role of urotensin II: effect of chronic infusion in the rat Peptides 25 10 (October) 2004 1783 1788
24. S.H. Kubo, T.S. Rector, A.J. Bank, R.E. Williams, and S.M. Heifetz Endothelium-dependent vasodilation is attenuated in patients with heart failure Circulation 84 4 (October) 1991 1589 1596
25. Z. Lacza, and W. Busija Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig Life Sci 78 23 (May) 2006 2763 2766
26. H. Lapp, G. Boerrigter, L.C. Costello-Boerrigter, K. Jaekel, T. Scheffold, and I. Krakau Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy Int J Cardiol 94 1 (March) 2004 93 97
27. L. Li, W.J. Yuan, and D.F. Su Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart Acta Pharmacol Sin 25 11 (November) 2004 1444 1449
28. M. Lim, S. Honisett, C.D. Sparkes, P. Komesaroff, A. Kompa, and H. Krum Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure Circulation 109 10 (March) 2004 1212 1214
29. G. Loirand, P. Guerin, and P. Pacaud Rho kinases in cardiovascular physiology and pathophysiology Circ Res 98 3 (February) 2006 322 334
30. J.J. Maguire, and A.P. Davenport Is urotensin-II the new endothelin? Br J Pharmacol 137 5 (November) 2002 579 588
31. E. Miche, G. Herrmann, M. Nowak, U. Wirtz, M. Tietz, and M. Hurst Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure Clin Res Cardiol 95 Suppl. 1 (January) 2006 i117 i124
32. L.L. Ng, I. Loke, R.J. O'Brien, I.B. Squire, and J.E. Davies Plasma urotensin in human systolic heart failure Circulation 106 23 (December) 2002 2877 2880
33. K. Noma, N. Oyama, and J.K. Liao Physiological role of ROCKs in the cardiovascular system Am J Physiol Cell Physiol 290 3 (March) 2006 C661 C668
34. D. Onan, L. Pipolo, E. Yang, R.D. Hannan, and W.G. Thomas Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases Mol Endocrinol 18 9 (September) 2004 2344 2354
35. E. Ovcharenko, Z. Abassi, I. Rubinstein, A. Kaballa, A. Hoffman, and J. Winaver Renal effects of human urotensin-II in rats with experimental congestive heart failure Nephrol Dial Transplant 21 5 (May) 2006 1205 1211
36. A.M. Richards, M.G. Nicholls, J.G. Lainchbury, S. Fisher, and T.G. Yandle Plasma urotensin II in heart failure Lancet 360 9332 (Aug) 2002 545 546
37. K. Riento, P. Villalonga, R. Garg, and A. Ridley Function and regulation of RhoE Biochem Soc Trans 33 Pt 4 (August) 2005 649 651
38. W.J. Rossowski, B.L. Cheng, J.E. Taylor, R. Datta, and D.H. Coy Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists Eur J Pharmacol 438 3 (March) 2002 159 170
39. F.D. Russell, and P. Molenaar Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart Cardiovasc Res 63 4 (September) 2004 673 681
40. O.O. Saetrum, H. Nothacker, F.J. Ehlert, and D.N. Krause Human urotensin II mediates vasoconstriction via an increase in inositol phosphates Eur J Pharmacol 406 2 (October) 2000 265 271
41. V. Sauzeau, M.E. Le, J. Bertoglio, E. Scalbert, P. Pacaud, and G. Loirand Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase Circ Res 88 11 (June) 2001 1102 1104
42. A.P. Somlyo, and A.V. Somlyo Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II J Physiol 522 Pt 2 (January) 2000 177 185
43. B. Sondermeijer, A. Kompa, P. Komesaroff, and H. Krum Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension Am J Hypertens 18 9 Pt 1 (September) 2005 1195 1199
44. A. Stirrat, M. Gallagher, S.A. Douglas, E.H. Ohlstein, C. Berry, and A. Kirk Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries Am J Physiol Heart Circ Physiol 280 2 (February) 2001 H925 H928
45. K. Tasaki, M. Hori, H. Ozaki, H. Karaki, and I. Wakabayashi Mechanism of human urotensin II-induced contraction in rat aorta J Pharmacol Sci 94 4 (April) 2004 376 383
46. X. Wang, B. Ren, S. Liu, E. Sentex, P.S. Tappia, and N.S. Dhalla Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat J Appl Physiol 94 2 (February) 2003 752 763
47. Z.J. Wang, L.B. Shi, Z.W. Xiong, L.F. Zhang, L. Meng, and D.F. Bu Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout Peptides 27 4 (April) 2006 858 863
48. T. Watanabe, T. Kanome, A. Miyazaki, and T. Katagiri Human urotensin II as a link between hypertension and coronary artery disease Hypertens Res 29 6 (June 1) 2006 375 387
49. A.P. Wheeler, and A.J. Ridley Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility Exp Cell Res 301 1 (November 1) 2004 43 49
50. A. Yoneda, H.A. Multhaupt, and J.R. Couchman The Rho kinases I and II regulate different aspects of myosin II activity J Cell Biol 170 3 (August) 2005 443 453